- Conditions
- Bleeding
- Interventions
- 60mg edoxaban, 180mg edoxaban, 50 IU/kg Beriplex P/N, 25 IU/kg Beriplex P/N, 10 IU/kg Beriplex P/N
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2257–2280
of 17,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Small Cell Lung Cancer
- Interventions
- Tarlatamab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Miami Beach, Florida • Stuart, Florida + 6 more
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- ibrutinib, Placebo, Prednisone
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 38
- States / cities
- Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 29 more
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- TmCD19-IL18
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2041
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Frailty
- Interventions
- Ghrelin Infusion - Healthy, Ghrelin Infusion - Frail, Placebo Infusion -Healthy, Placebo Infusion - Frail
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 70 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Social Anxiety Disorder
- Interventions
- PH94B, Placebo
- Drug · Other
- Lead sponsor
- Pherin Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Renal Cell, Melanoma
- Interventions
- GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 6
- States / cities
- Bethesda, Maryland • Boston, Massachusetts • Cambridge, Massachusetts + 2 more
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma
- Interventions
- Nemvaleukin Alfa Subcutaneous, Nemvaleukin Alfa Intravenous, Nemvaleukin Alfa Intravenous Less Frequent Dosing, Pembrolizumab
- Drug
- Lead sponsor
- Mural Oncology, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Jacksonville, Florida + 5 more
- Conditions
- Breast Cancer
- Interventions
- BB-1701
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 27
- States / cities
- Los Alamitos, California • Los Angeles, California • San Francisco, California + 22 more
- Conditions
- Head and Neck Cancer
- Interventions
- Ad/PNP and fludarabine monophosphate
- Genetic
- Lead sponsor
- PNP Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Nashville, Tennessee
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Interventions
- Venetoclax, Decitabine
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Sacramento, California • The Bronx, New York • White Plains, New York
- Conditions
- Substance Use Disorders, Methamphetamine Abuse, Methamphetamine Intoxication
- Interventions
- CS-1103, Sterile Saline
- Drug
- Lead sponsor
- Clear Scientific, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- HER2 Positive Breast Cancer, Left Ventricular Function Systolic Dysfunction
- Interventions
- Trastuzumab, Pertuzumab, Ado Trastuzumab Emtansine
- Drug
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Breast Cancer
- Interventions
- Goserelin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 15 Years to 46 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy Participants
- Interventions
- Lu AH69593, Itraconazole, Carbamazepine, Midazolam
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Advanced Cancer
- Interventions
- Irinotecan
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Evanston, Illinois
- Conditions
- Brain Metastases
- Interventions
- Bendamustine
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Steroid-Refractory Acute Graft Versus Host Disease
- Interventions
- T-Guard, Ruxolitinib
- Drug
- Lead sponsor
- Xenikos
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Duarte, California • Tampa, Florida + 9 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Panitumumab, Carboplatin, Paclitaxel, Intensity Modulated Radiation Therapy, 5-Fluorouracil, Docetaxel, Cisplatin
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
- Interventions
- VIR-1388, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Boston, Massachusetts
- Conditions
- External Cephalic Version
- Interventions
- Intravenous Terbutaline, Intravenous Nitroglycerine
- Drug
- Lead sponsor
- Yaakov Beilin
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cystic Fibrosis
- Interventions
- VX-659/TEZ/IVA, TEZ/IVA, IVA, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 25 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Indocyanine green, Near-infrared fluorescence imaging
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- Cemiplimab, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri